Beyond Air, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Beyond Air, Inc. on June 18, 2025. The filing covers corporate events occurring on June 16 and June 17, 2025, including the announcement of financial results for the fiscal quarter and year ended March 31, 2025, the appointment of a new director, and a regulatory submission to the FDA.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing financial results for the quarter and year ended March 31, 2025. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for detailed financial data.
Material Changes and Corporate Events
- Board Appointment: On June 16, 2025, the Board appointed Robert Goodman as an independent director. Mr. Goodman brings experience from BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer.
- Regulatory Submission: On June 16, 2025, the Company submitted a premarket approval (PMA) supplement application to the U.S. FDA for LungFit PH II, its next-generation therapeutic nitric oxide generator.
- Financial Results: On June 17, 2025, the Company announced results for the fiscal period ended March 31, 2025, though specific figures are not detailed in this document.
Guidance, Outlook, and Risks
The filing does not contain explicit forward-looking guidance, management commentary on future performance, or a discussion of specific risks and contingencies beyond the standard regulatory context. The submission of the PMA supplement for LungFit PH II represents a significant milestone in the Company's product development pipeline.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release dated June 17, 2025) for specific revenue, net income, and cash position figures for the quarter and year ended March 31, 2025.
- Monitor the status of the PMA supplement application for LungFit PH II submitted to the FDA on June 16, 2025.
- Confirm the committee assignments and compensation details for the newly appointed director, Robert Goodman, in future filings.